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Recently, the complete genome sequence of Campylobacter jejuni NCTC 11168 was 
published revealing the presence of only one open reading frame (Cj1411c) 
encoding for a cytochrome P450, in contrast to 20 found in M. tuberculosis. The 
gene Cj1411c encodes for a soluble 52.6 kDa protein with a predicted isoelectric 
point of 9.3. The P450 gene is part of reading frame which hosts genes involved in 
the synthesis of cell surface components (capsula). Campylobacter capsule are 
important in adherence, invasion and colonisation of host cells and for maintenance 
of cell surface charge and serum resistance. These capsule are thought to cause 
autoimmunity leading to Guillan-Barre and Miller-Fischer syndromes. The structure 
of the lipoolygosaccharides and capsule polysaccharide was published last year 
revealing that the strain possessed a type II/III capsule locus found in other 
microorganisms such Nisseria meningitidis. This project focuses on the cloning and 
characterisation of the only P450 enzyme of the human pathogen Campylobacter 
jejuni NCTC 11168. We aim to understand the metabolic role of this P450 
cytochrome in order to elucidate its possible use as a new target for drug design. To 
achieve this aim we have cloned, expressed and purify the product of P450 coding 
gene. 
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Introduction 
 
The Campylobacter jejuni 11168 P450 is unique among the P450 enzymes 
by its unusual location, no other enzymes are known to be located in an operon 
involved in cell surface biosynthesis (Teramoto, 2004; Kelly, 2001). His closest 
homologues were identified in Polaromonas sp. (38 % identity) and Silicobacter 
sp.(34 % identitiy). Silicibacter sp. TM1040 is a member of the Roseobacter of the 
alpha-proteobacteria, which is among the most abundant and ecologically relevant 
marine bacterial groups. Polaromonas strain JS666 (ATCC No. BAA-500), a 
member of the family Comamonadaceae in the beta-proteobacteria, is a novel,   19
aerobic, cis-dichloroethene (cDCE)-assimilating organism with optimum growth at 
20-25¾C. Strain JS666 is closely related to the Antarctic marine isolate 
Polaromonas vacuolata (Allos, 1995; Altschul, 1997; Andersen, 1993; 
Anzenbacher, 2001). Both of these genes are involved in carbohydrate metabolism 
(ascorbate and aldarate) (Allos, 1997; Bacon 2001).The sequence alignment of 
these two enzymes with the Campylobacter jejuni P450 is presented in figure 
4.The cytochrome P450 coding sequence (Cj1411c) of Campylobacter jejuni 
11168 is 1359 bp long. Is located in an open reading frame with an unusual number 
of genes (40 genes), from which 55 % of the genes involved in sugar or 
polysaccharide biosynthesis. The remaining 45 % is represented by unknown 
proteins and few amino acid transferases. In the primary structure the protein 
contains 453 amino acids having at the C-terminal the characteristic protoporpyrin 
IX binding motif. In secondary structure the protein is dominated by helixces with 
few coils and strands.Mitochondrial and bacterial P450 systems have three 
components: and FAD-containing flavoprotein (NADPH or NADH-dependant 
reductase), an iron-sulfur protein and P450. By comparison with the P450 Rhf 
isolated from Rhodococcus sp. NCIMB 9784, where the reductase domain is an 
FMN-FeS domain fused to the N-terminal heme-containing oxygenase, in 
Campylobacter jejuni 11168 the reductase components are not fused in a single 
polypeptide. The FMN was identified under Cj1382c and Fe-S under Cj1377c. 
Having all the components separate the Campylobacter  P450 reductase is 
represented under a new class (class V – figure 1). 
 
 
 
 
Fig. 1. Diagram of the possible class V of P450 reductases. 
 
The aim of this work was to clone, express and purify the only bacterial 
cytochrome P450 located in a genomic locus which is charcaterised by the 
presence of genes involved in sugar and surface structures biosynthesis. 
 
Material and Methods 
 
For cloning and expression of the cytochrome P450 a system constructed by 
Novagen UK called Perfectly Blunt Cloning Kits (technical details presented 
across the chapter) which are designed for cloning of any DNA fragment which has 
5' overhangs and 3' overhangs was used. The DNA fragments are made blunt-
ended by a single step reaction followed by a heat inactivation step and then the 
fragments are ligated in to the dephosphorylated vector. The recombinant plasmid 
NAD(P)H
FeS
Heme FMN
NAD(P)+ NAD(P)H
FeS
Heme Heme FMN
NAD(P)+  20
is transformed in E. coli NOVA BLUE and positive colonies are identified by blue 
/ white screening (pETBlue-1 Blunt vector Manual, NOVAGEN). The pETBlue
TM 
Perfectly Blunt Cloning Kits include Tuner
TM(DE3)placI competent cells for 
expression. This strain carries a chromosomal copy of the T7 RNA polymerase 
gene. The expression of the target proteins is controlled by the T7lac promoter 
which is IPTG inducible. The strain NOVA BLUE is used like a mother strain 
which allows us to check the constructs. The system is suitable for inserts which 
have an ATG start codon. 
 
Results and Discussion 
For genomic DNA preparation Campylobacter jejunui NCTC 11168 strain 
was grown on Mueller-Hinton Broth for 42 hours in an atmosphere containing 5 % 
O2, 10 % CO2 and 85 % N2 in a microaerobic box. Cells were harvested by 
centrifugation when they reached the stationary phase and genomic DNA was 
extracted using Wizard Genomic Kit from Promega. P450 gene was amplified from 
genomic DNA by PCR using the primers Cj1411cFOR and Cj1411cREV. 
Amplification was made using Promega PFU polymerase to avoid any possible 
mutation during PCR. The PCR reaction was performed using 5pmol of each 
primer and 1.25 U of PFU polymerase. The total volume of reaction was 50 l  
PCR steps: 
Step I: 95 
0C for 1 minute - 1 cycle 
Step II: 95 
0C for 30 seconds 
53.2 
0C for 30 seconds      32 cycles 
72 
0C for 2 minutes 
Step III: 72 
0C for 5 minutes - 1 cycle 
After amplification each reaction mix was checked in 0.8 % agarose gel and 
in each case a fragment of the expected size (1359 bp) was observed (fig. 2). PCR 
reactions were stored at -20 
0C until the next cloning step was performed. 
After gel purification the fragment was ligated in pETBlue-1 Blunt vector. 
The purified insert was cloned into the EcoRV site which is located such that an 
insert will specify the N terminus of the expressed protein.  
After ligation the transformation was performed with E. coli Nova Blue 
competent cells. After transformation, cells were plated on LB solid media 
supplemented with carbenicilin (50 μg / ml) and tetracycline (15 μg / ml).   21
 
 
 
Transformation was performed as described in material and methods. For 
blue/white screening X-gal and IPTG were added to the media, prior to plating the 
cells and the plates were incubated overnight at 37 
0C. There were no mutations 
detected in the sequence. Using the same protocol, but using the primers 
Cj1411cFOR and Cj1411cREVHIS, we also constructed a gene encoding a 
recombinant protein with a 6 HIS Tag at the C terminus of the sequence. The 
construct was cloned into the pETBlue1 Blunt vector and expressed in E. coli 
Tuner (DE3) placI. The plasmid has been named pBP450CjCHIS. For expression 
the recombinant plasmid pBP450Cj was used to transformed Tuner
 (DE3) placI. 
Cells resistant to carbenicilin (50 μg / ml) and chloramphenicol (34 μg / ml) have 
been used for protein expression. Expression trials were performed in 100 ml flasks 
containing LB + 1 % glucose and the appropriate antibiotics which were inoculated 
with 1 ml of o/n culture. Cultures were than incubated at 37 
0C by shaking at 200 
rpm until the cultures has reached 0.5 O.D. For expression cells were induced with 
1 mM IPTG and samples were taken at different intervals for testing the protein 
expression. For protein expression tests 1 ml of cell culture was centrifuged and the 
pellet diluted in 50 μl water. The pellet was boiled for 5 minutes and 2 μl of 
solution was mixed with 5 μl SDS PAGE loading buffer and water up to 15 μl. 
Samples were run in 15 % SDS PAGE gel and the proteins visualised by coomassie 
staining (fig. 3). The red coloured pellet characteristic of P450 expression appeared 
after 24 hours. The native enzyme was identified by spectral characterisation and 
CO binding reaction. A 450 nm peak was observed in whole cell extracts (fig. 4). 
Fig. 2. Visualisation of PCR results in agarose gel. PCR 1,2 and 3 have be done by using 1 
µl genomic DNA and 0.5 µl for PCR 4, 5, and 6. 3 µl from each reaction have been used in 
the gel.   22
 
 
 
 
Fig. 4. Expression identified by 450 nm absorption in SORET band with CO bound. 
Sample preparation: cell membranes were disrupted by sonication, centrifuged and 
supernatant collected. To reduce the protein sodium dithionite was used and CO was 
bubbled into the sample. Successive spectra shows the transition of the 420 nm peak, of the 
oxidised protein, to 450 nm peak by exposure of the protein to the CO. 
 
The initial purification trials were started with the anion exchange resins 
DEAE Sephacel and Q sepharose and with hydroxyapatite, using TRIS-HCl buffer, 
HEPES (pH 6.8-8.2), Phosphate buffer (pH 6-8) and CAPS (pH 9.7-11). 
Unfortunately the protein did not bind to the resins in any of these conditions. The 
same problems were faced with the cation exchangers C25 and CM 
(carboxymethyl cellulose) at pH 7 the protein came through the column without 
any binding. The next attempts were to try the hydrophobic resins: phenyl 
sepharose, octyl sepharose, decyl sepharose, butyl sepharose. None of these 
columns provided a good purification. The protein was bound to the phenyl 
sepharose column but it could not be eluted. For purification, eight flasks 
containing 1.5 L LB, 1 % glucose and the appropriate antibiotics (see materials and 
methods) were inoculated with 5 ml of Tuner (DE3)placI containing the plasmid 
pBP450Cj. Cultures were grown at 37 
0C for ~ 6 hours or until the cultures reached 
0.5 O.D. by shaking at 230 rpm. Cells were induced for protein expression with 1 
mM IPTG and incubated for another 24 hours at 18 
0C. After 24 hours cells were 
harvested in 0.5 L bottles in a RC-5B centrifuge at 8000 rpm and the pellet was 
washed with 20 mM triethanolamine - HCl at pH 8 and centrifuged again for 
Fig. 3. Visualisation of protein expression using 15 % SDS-PAGE and stained with 
Coomassie Blue. Lane 1 – cells only (no plasmid), Lane 2 – uninduced (no IPTG), Lane 3 
– marker, Lane 4 – expression after 8 hours, Lane 5 – expression after 24 hours   23
collection. Cells were again resuspended in 20 mM triethanolamine - HCl at pH 8 
and cells sonicated as described in materials and methods. Cell lysate was 
centrifuged for 30 minutes at 15000 rpm in a RC-5B centrifuge and the supernatant 
kept. The supernatant was than treated with 40 mg RNaseA and 0.9 mg DNaseI 
and was gently mixed for 35 minutes at room temperature. The pellet was than 
centrifuged again for 30 minutes at 15000 rpm in a RC-5B centrifuge. In the next 
step the supernatant was treated with protamine sulphate (200 mg / l culture) and 
mixed occasionally for 15 minutes at room temperature. Then the pellet was 
centrifuged at 11200 rpm for 30 minutes at 4 
0C and the supernatant retained. The 
supernatant was frozen at –20 
0C or used directly in the purification steps and a 
small volume was used to check the activity. Purification of the P450 enzyme was 
done using a DE52 resin by using the following protocol:(i) after treating with 
RNaseA, DNaseI and protamine sulphate the crude cell extract was loaded into a 
100 ml column containing DE52 resin equilibrated with 300 ml 20 mM 
triethanolamine – HCl, pH 8. The P450 protein is coming through the column and a 
part other proteins from the solution binds to the resin. (ii) the red fraction was 
concentrated and dialysed o/n to change the buffer to ml 20 mM, triethanolamine – 
HCl, pH 8 and 200 mM KCl and was loaded into a DE52 column equilibrated in 
the same buffer. (iii) to achieve a better purification the protein was loaded into the 
third DE52 column. All the fractions were verified by SDS-PAGE and stained with 
Coomassie blue (fig.5).  
 
 
 
 
 
 
 
 
 
The protein concentration was approximated to 12.5 mg / ml and was 
calculated using the SORET absorption. The concentrated protein was frozen at –
80 
0C until further experiments were preceded.  
 
Conclusions 
 
This paper describes the work carried out on the cytochrome P450 enzyme 
from  Campylobacter jejuni 11168. Sequencing in 2000 of the Campylobacter 
1  2  3  4 
Fig. 5. Purification on DE52 – 
fractions visualisation on 15 % 
SDS-PAGE and Coomassie Blue 
Staining: 
 
1.  First DE52 after 
RNaseA, DNaseI and 
protamine sulphate 
treatment 
2.  Second DE52  
3.  Third DE52   24
jejuni 11168 genome revealed the presence of a cytochrome P450 coding sequence 
which was proved to be unique by its localisation in an operon involved in cell 
surface biosynthesis. This cytochrome P450 was identified to be conserved among 
the Campylobacter jejuni strains by its presence in Campylobacter jejuni RM1221 
(Aspinall, 1994, 1993). The recombinant protein was successfully over-expressed 
using pETBlue1 Blunt as vector and E. coli Tuner (DE3) placI as expression strain, 
this study being a very useful tool for expression of recombinant P450s. 
Purification of this cytochrome P450 was not completely successful but 70 % 
purity was achieved using DE52 anion-exchange and triethanolamine as a buffer at 
pH 8. Purification was done in reverse way by collecting the red fraction which ran 
through the column. The red fraction collected was concentrated up to 12 mg/ml 
but at this concentration the protein proved to be cloudy and very viscous. To 
improve the purity of the protein to HIS-Tagged constructs were prepared (one 
with the 6HIS at the N terminus and one at the C terminus) but the purification 
trials failed as the protein was not bound to the nickel column. By comparison with 
the P450 Rhf isolated from Rhodococcus sp. NCIMB 9784, where the reductase 
domain is an FMN-FeS domain fused to the N-terminal heme-containing 
oxygenase, in Campylobacter jejuni 11168 the reductase components are not fused 
in a single polypeptide. The FMN was identified under Cj1382c and Fe-S under 
Cj1377c. Having all the components separate the Campylobacter P450 reductase is 
represented under a new class. Being the only cytochrome P450 known to be 
involved in sugar metabolism future work must be done on purification and in 
trying to obtain a crystal structure which would be a major step helping to 
understand the interaction with electron transfer partners. Biochemical studies must 
be developed on kinetics of the enzyme giving insights in the function of this novel 
enzyme and to identify the substrate and the product. On the biological side further 
experiments must be conducted to study the difference in adhesion and infectivity 
between the wild type strain and a P450 deficient strain. Because of its location in a 
reading frame in which all the genes are involved in surface structure biosynthesis 
it is very important to investigate the phenotypic behaviour of a P450 deficient 
strain. The results obtained following these experiments could be very important 
for the pharmaceutical industry that is looking for new targets in creating an 
efficient vaccine against Campylobacter spp. 
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